Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer

Cancer

Volumn 109, Issue 12, 2007, Pages 2615-2622

  Ansari, Shoaib R ^a   Hanna, Hend ^a   Hachem, Ray ^a   Jiang, Ying ^a   Rolston, Kenneth ^a   Raad, Issam ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Drug resistance; Stenotrophomonas maltophilia infection; Trimethoprim sulfamethoxazole (TMP SMX)

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TETRACYCLINE DERIVATIVE; TIMENTIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SOLID TUMOR; STENOTROPHOMONAS MALTOPHILIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 34250331614     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22705     Document Type: Article

References (40)

1. Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000;31:705-711.
2. Khardori N, Elting L, Wong E, Schable B, Bodey GR Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990;12:997-1003.
3. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11:57-80.
4. Spangler SK, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob Agents Chemother. 1996; 40:772-775.
5. Vartivarian SE, Papadakis KA, Palacios JA, Manning JT Jr, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med. 1994;121:969-973.
6. Vartivarian SE, Papadakis KA, Anaissie EJ. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med. 1996;156:433-435.
7. Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg. 1997;87: 106-108.
8. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999;11:28-33.
9. Van Couwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol. 1997;18:316-321.
10. Gopalakrishnan R, Hawley HB, Czachor JS, Markert RJ, Bernstein JM. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals. A study of 143 patients. Heart Lung. 1999;28:134-141.
11. Carroll KC, Cohen S, Nelson R, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 1998;32: 229-235.
12. Smit WJ, Boquest AL, Geddes JE, Tosolini FA. The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management. Pathology. 1994;26:321-324.
13. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994;38:624-627.
14. Garrison MW, Anderson DE, Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother. 1996;40: 2859-2864.
15. Fass RJ, Barnishan J, Solomon MC, Ayers LW. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother. 1996; 40:1412-1418.
16. Penzak SR, Abate BJ. Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy. 1997;17:293-301.
17. Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22:508-512.
18. Saino Y, Kobayashi F, Inoue M, Mitsuhashi S. Purification and properties of inducible penicillin b-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother. 1982;22:564-570.
19. Saino Y, Inoue M, Mitsuhashi S. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother. 1984; 25:362-365.
20. Wishart MW, Riley TV. Infection with Pseudomonas maltophilia: hospital outbreak due to contaminated disinfectant. Med J Aust. 1976;2:710-712.
21. Marshall WF, Keating MR, Anhalt JP, Steckelberg JM. Xanthomonas maltophilia: an emerging nosocomial pathogen. Mayo Clin Proc. 1989;64:1097-1104.
22. Gales AC, Jones RN, Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001;15;32(suppl 2): S104-113.
23. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-140.
24. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001;32:1055-1061.
25. Paterson DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st century approach. Clin Infect Dis. 2002;34:1564-1567.
26. Pradhananga SL, Rowling PJ, Simpson IN, Payne DJ. Sensitivity of L-2 type beta-lactamases from Stenotrophomonas maltophilia to serine active site beta-lactamase inhibitors [letter]. J Antimicrob Chemother. 1996;37:394-396.
27. Crowder MW, Walsh TR, Banovic L, Pettit M, Spencer J. Overexpression, purification, and characterization of the cloned metallo-betalactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1998;42:921-926.
28. Zhang L, Xian-Zhi L, Poole K. Multiple antibiotic resistance in Stenotrophomonas: involvement of a multidrug efflux system Antimicrob Agents Chemother. 2000;44:287-293.
29. Elting LS, Khardori N, Bodey GR Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990;11:134-138.
30. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005;104:205-212.
31. Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004;37:359-365.
32. Spanik S, Krupova I, Trupl J, et al. Bacteremia due to multiresistant Gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Infect Chemother. 1999; 5:180-184.
33. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmei Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999;28:1128-1133.
34. Elting LS, Bodey GE Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore). 1990;69:296-306.
35. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia [review]. J Hosp Infect. 1995;30(suppl):453- 464.
36. Morrison AJ, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol. 1986; 24:52-55.
37. Vartivarian SE, Papadakis K, Anaissie EJ. Outcome of Stenotrophomonas maltophilia infections in cancer patients. In: Program and Abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract J-92), September 28-October 1, 1997, Toronto, Ontario, Canada.
38. Tsiodras S, Pittet D, Carmeli Y, et al. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprimsulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis. 2000;32:651-656.
39. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 2002;44:259-263.
40. Garcia Sanchez JE, Vazquez Lopez ML, Blazquez AM, et al. Aztreonam/clavulanic acid in the treatment of serious infections caused by Stenotrophomonas maltophilia in neutropenic patients: case reports. J Chemother. 1997;9: 238-240.